The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Would it be flip of me to say, “A whole bunch of stuff?” It’s one of the main reasons I was attracted to the practice in the ...

What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes ...

A study published in The Lancet Child & Adolescent Health looks at myocarditis and vascular and inflammatory diseases after COVID-19 infection and vaccination in children. Prof Saidi (Sam) Mohiddin, ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

Psychedelics and Parkinson’s may trigger hallucinations through the same system, revealing how fragile the balance is between externally and internally generated perception.

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

It’s notoriously tough to land a political blow on Donald Trump, but California congressman Ro Khanna is one of the few ...

At a margin of 40%, Palantir delivered $476 million net income (GAAP). Overall, the company now has $6.4 billion in cash and cash equivalents. More importantly for investors, Palantir raised its FY ...

Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...